General
Preferred name
OXYMETAZOLINE
Synonyms
OXYMETAZOLINE HYDROCHLORIDE ()
Oxymetazoline HCl ()
oxymetazoline, Allergan ()
AFRAZINE ()
AGN-199201 ()
NSC-757254 ()
OCUCLEAR ()
OXIMETAZOLINE HYDROCHLORIDE ()
OXYMETAZOLINE HYDROCHLORIDE COMPONENT OF KOVANAZE ()
RHOFADE ()
SCH 9384 ()
SCH-9384 ()
UPNEEQ ()
VISINE L.R. ()
Nasacon ()
Oximetazolina ()
Operil ()
Afrin ()
Oxymetazoline (hydrochloride) ()
P&D ID
PD009632
CAS
2315-02-8
1491-59-4
Tags
available
biased GPCR ligand
drug
Approved by
FDA
First approval
1986
Drug indication
Allergic rhinitis
Seasonal allergic rhinitis
Nasal congestion
Eye inflammation
Drug Status
approved
investigational
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Oxymetazoline is a selective α1-adrenoceptor agonist and α2-adrenoceptor partial agonist with vasoconstricting properties.
(GtoPdb)
DESCRIPTION
α1A agonist
(Tocriscreen Total)
DESCRIPTION
Partial alpha2A adrenoceptor agonist; agonist at serotonin 5-HT1A, 5-HT1B and 5-HT1D receptors and a mixed agonist-antagonist at 5-HT2C receptors
(LOPAC library)
DESCRIPTION
Oxymetazoline is an alpha-1A adrenoceptor agonist. It is used to treat nasal congestion, allergic reactions of the eye, and facial erythema associated with rosacea.
(Enamine Bioactive Compounds)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
0
Organisms
1
Compound Sets
34
AdooQ Bioactive Compound Library
BiasDB
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
Concise Guide to Pharmacology 2025/26
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
Enamine Bioactive Compounds
EU-OPENSCREEN Bioactive Compound Library
EUbOPEN Chemogenomics Library
Guide to Pharmacology
Ki Database
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
NCATS Inxight Approved Drugs
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
The Spectrum Collection
Tocriscreen Total
ZINC Tool Compounds
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
244
Molecular Weight
260.19
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
2
Rotatable Bonds
2
Ring Count
2
Aromatic Ring Count
1
cLogP
2.85
TPSA
44.62
Fraction CSP3
0.56
Chiral centers
0.0
Largest ring
6.0
QED
0.86
QED
0.86
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Selectivity
alpha2A
Target
¦Á-adrenergic receptor
¦Á2-adrenergic receptor
ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR2C
Member status
member
MOA
alpha1A-Adrenoceptor Agonists
alpha2A(2D)-Adrenoceptor Agonists
Adrenergic Receptor agonist
Indication
nasal congestion
Therapeutic Class
Nasal Decongestants
Recommended Cell Concentration
10 nM
Source data

